02942: Genome-wide Molecular Interrogation of Canine Hemangiosarcoma
Grant Status: Open
Hemangiosarcoma (HSA) is often called a “silent killer” because dogs with splenic forms of this disease usually do not show clinical signs until it is too late. Importantly, once at the hospital, it can be very difficult for clinicians to tell with certainty whether the mass is malignant or benign without removing the spleen (which is expensive) and performing histopathological analysis on the mass (which can take days to complete). Given this inability to distinguish HSA from benign disease at the time of initial presentation, there is an urgent need to develop new biomarkers that can rapidly differentiate HSA from non-life-threatening conditions so that owners can make informed decisions regarding the course of treatment. Investigators have recently begun to analyze gene expression in HSA tumors using a novel genome-wide technique called Chromatin-Run-On sequencing (ChRO-seq) in order to better document the molecular nature of HSA. In this study, investigators will expand on these initial studies and now use ChRO-seq and other cutting-edge genome-wide technologies to identify gene signatures and molecular features of these tumors. Outcomes from this study may also speed up the development of early detection screening tools for high risk dogs and help with prognosis in dogs with HSA.
None at this time.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.